Genomic risk model to implement precision prostate cancer screening in clinical care: the ProGRESS study.
Vassy JL, Dornisch AM, Karunamuni R, Gatzen M, Kachulis CJ, Lennon NJ, Brunette CA, Danowski ME, Hauger RL, Garraway IP, Kibel AS, Lee KM, Lynch JA, Maxwell KN, Ratner D, Rose BS, Teerlink CC, Xu GJ, Hofherr SE, Lafferty KA, Larkin K, Malolepsza E, Patterson CJ, Toledo DM, Donovan JL, Hamdy FC, Martin RM, Neal DE, Turner EL, Andreassen OA, Dale AM, Mills IG, Abraham A, Batra J, Clements J, Cussenot O, Cybulski C, Eeles RA, Fowke JH, Grindedal EM, Grönberg H, Hamilton RJ, Lim J, Lu YJ, MacInnis RJ, Maier C, Mucci LA, Multigner L, Neuhausen SL, Nielsen SF, Parent MÉ, Park JY, Petrovics G, Plym A, Razack A, Rosenstein BS, Schleutker J, Sørensen KD, Townsend PA, Travis RC, Vega A, West CML, Wiklund F, Zheng W; Profile Steering Committee; IMPACT Study Steering Committee and Collaborators; PRACTICAL Consortium; VA Million Veteran Program; Seibert TM.
Vassy JL, et al. Among authors: andreassen oa.
Nat Cancer. 2026 Jan 26. doi: 10.1038/s43018-025-01103-0. Online ahead of print.
Nat Cancer. 2026.
PMID: 41588240